Methods of treating fabry patients having renal impairment
Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
1. A method of treating Fabry disease in an ERT-experienced female patient with normal renal function with an eGFR of at least 90 mL/min/1.73 m 2 and with a HEK assay amenable mutation in α-galactosidase A, the method comprising administering to the patient about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day.
2. The method of claim 1 , wherein the administration of the migalastat is effective to stabilize renal function in the patient.
3. The method of claim 2 , wherein administration of an effective amount of the migalastat to a group of ERT-experienced female patients having normal renal function with eGFRs of at least 90 mL/min/1.73 m 2 and HEK assay amenable mutations in α-galactosidase A provides a mean annualized rate of change in eGFR CKD-EPI of greater than −1.5 mL/min/1.73 m 2 .
4. The method of claim 1 , wherein the administration is effective to provide an annualized rate of change in eGFR CKD-EPI of greater than −3.0 mL/min/1.73 m 2 .
5. The method of claim 1 , wherein the administration is effective to provide an annualized rate of change in eGFR CKD-EPI of greater than −1.5 mL/min/1.73 m 2 .
6. The method of claim 1 , comprising administering about 123 mg FBE of migalastat at a frequency of every other day.
7. The method of claim 6 , comprising administering about 150 mg of migalastat hydrochloride at a frequency of every other day.
8. The method of claim 6 , wherein the migalastat is administered to the patient for at least 2 years.
9. The method of claim 8 , wherein the migalastat is administered to the patient for at least 5 years.
10. The method of claim 6 , wherein the migalastat is administered orally in solid dosage form.
11. A method of treating Fabry disease in an ERT-naïve female patient with mild renal impairment with an eGFR of 60 to 90 mL/min/1.73 m 2 and with a HEK assay amenable mutation in α-galactosidase A, the method comprising administering to the patient about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day.
12. The method of claim 11 , wherein the administration of the migalastat is effective to stabilize renal function in the patient.
13. The method of claim 12 , wherein administration of an effective amount of the migalastat to a group of ERT-experienced female patients having normal renal function with eGFRs of at least 90 mL/min/1.73 m 2 and HEK assay amenable mutations in α-galactosidase A provides a mean annualized rate of change in eGFR CKD-EPI of greater than −0.1 mL/min/1.73 m 2 .
14. The method of claim 11 , wherein the administration is effective to provide an annualized rate of change in eGFR CKD-EPI of greater than −4.0 mL/min/1.73 m 2 .
15. The method of claim 11 , wherein the administration is effective to provide an annualized rate of change in eGFR CKD-EPI of greater than −0.1 mL/min/1.73 m 2 .
16. The method of claim 11 , comprising administering about 123 mg FBE of migalastat at a frequency of every other day.
17. The method of claim 16 , comprising administering about 150 mg of migalastat hydrochloride at a frequency of every other day.
18. The method of claim 16 , wherein the migalastat is administered to the patient for at least 2 years.
19. The method of claim 18 , wherein the migalastat is administered to the patient for at least 5 years.
20. The method of claim 16 , wherein the migalastat is administered orally in solid dosage form.